undamentalytics Newsletter
Sign in

Travere Therapeutics, Inc. cash flow statement

In fiscal 2025, Travere Therapeutics, Inc.'s operations generated $37.8m of cash; it spent $0 on capital projects, leaving free cash flow of $37.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Feb 20112012Feb 20122016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−0—−37−25−58−43−15−186−280−23738177
Depreciation and amortisation——1618192025132139446153
Stock-based pay——2927202124303844374573
Capital spending—011107501000
Free cash flow——−57−26−58−50−20−186−281−23738177
Free cash flow after stock pay——−34−20−45−80−73−49−225−325−274−7104
Share buybacks——0——————————
Shares issued——00———18901911350—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EBS vs TVTXALVO vs TVTXAMPH vs TVTXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Travere Therapeutics, Inc.